Connect

Member Research and Reports

Member Research and Reports

HIV-Infected Children May Be Protected Against Puberty Delays by Newer Drugs

In a new study, researchers from Harvard School of Public Health found that newer combination antiretroviral (ARV) drug therapies for HIV appear to protect against puberty delays among children born with HIV. “We found that youth born with HIV do have a significantly later start to puberty than similar youth without HIV,” said lead author Dr. Paige Williams of the Center for Biostatistics in AIDS Research and senior lecturer on biostatistics. “Youth with the most severe HIV symptoms tended to have the greatest puberty delays. Our data also suggested, however, that over the past decade, combination HIV medications may help children with HIV start puberty at a more typical age.” Combination antiretroviral treatments consist of three or more drugs from two or more anti-HIV drug classes and are now standard therapy. Funded by the National Institutes of Health (NIH), the study is believed to be the first to evaluate the impact of combination HIV treatments on puberty onset in youth.”